Vimpat and Aprepitant drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vimpat (lacosamide) and Aprepitant (aprepitant). Common drug interactions include skin fissures among females and chronic obstructive pulmonary disease among males.

The phase IV clinical study analyzes what interactions people have when they take Vimpat and Aprepitant. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,832 Vimpat users. Check the latest studies of Vimpat.

What is Aprepitant?

Aprepitant has active ingredients of aprepitant. eHealthMe is studying from 6,992 Aprepitant users. Check the latest studies of Aprepitant.

On Aug, 08, 2026

19 people who take Vimpat and Aprepitant together, and have interactions are studied.

Vimpat and Aprepitant drug interactions.

What are the common drug interactions of Vimpat and Aprepitant, by gender? *:

female:

Skin fissures (a crack in the skin)
Thrombocytopenia (decrease of platelets in blood)
Influenza
Dehydration (dryness resulting from the removal of water)
Headache (pain in head)
White blood cell count decreased
Nausea (feeling of having an urge to vomit)
Hemianopia (blindness or reduction in vision in one half of the visual field due to damage of the optic pathways in the brain)

male:

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Hyperthyroidism (over activity of the thyroid gland)
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Disease progression
Platelet count decreased

What are the common drug interactions of Vimpat and Aprepitant, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

White blood cell count decreased
Hemianopia (blindness or reduction in vision in one half of the visual field due to damage of the optic pathways in the brain)
Nausea (feeling of having an urge to vomit)
Skin fissures (a crack in the skin)
Thrombocytopenia (decrease of platelets in blood)

40-49:

Thrombocytopenia (decrease of platelets in blood)
Influenza
White blood cell count decreased
Hemianopia (blindness or reduction in vision in one half of the visual field due to damage of the optic pathways in the brain)
Nausea (feeling of having an urge to vomit)
Skin fissures (a crack in the skin)

50-59:

n/a

60+:

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Hyperthyroidism (over activity of the thyroid gland)
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)

What are the existing conditions these people have? *

Nausea (feeling of having an urge to vomit): 9 people, 47.37%
Diarrhea: 9 people, 47.37%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 5 people, 26.32%
Sleep Disorder: 4 people, 21.05%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 21.05%
Headache (pain in head): 4 people, 21.05%
Depression: 4 people, 21.05%
Breast Cancer Metastatic: 4 people, 21.05%
Brain Neoplasm Malignant (brain cancer tumour): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and Aprepitant?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously